Form 4: Gyre Therapeutics President Sells Shares Under 10b5-1 Trading Plan

Songjiang Ma, President of Gyre Therapeutics, sold shares of common stock on February 4th and 5th, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• Songjiang Ma, President of Gyre Therapeutics, sold shares of the company's common stock on February 4th and 5th, 2025.
• The sales were executed under a Rule 10b5-1 trading plan adopted on September 13, 2024.
• On February 4, 2025, 2,000 shares were sold at a weighted average price of $11.62, with individual prices ranging from $11.33 to $11.87.
• On February 5, 2025, 1,980 shares were sold at a weighted average price of $12.39, with individual prices ranging from $11.82 to $12.81.
• Also on February 5, 2025, 20 shares were sold at a weighted average price of $12.84, with individual prices ranging from $12.835 to $12.84.
• Following these transactions, Songjiang Ma directly owns no shares and indirectly owns 2,883,138 shares through a spouse.

Sentiment

Score: 5

Explanation: The document is neutral as it simply reports stock sales under a pre-existing trading plan. There is no inherent positive or negative sentiment associated with this type of filing.

Risks

• Executive stock sales can sometimes be perceived negatively by the market, potentially impacting investor sentiment.

Industry Context

Sales by company presidents are common and are often part of personal financial planning. The use of a 10b5-1 plan suggests the sales were pre-planned and not based on inside information.

Stakeholder Impact

• The stock sales could have a minor impact on shareholders if the market perceives the sales negatively, although the use of a 10b5-1 plan mitigates this concern.

Key Dates